<code id='15D9882719'></code><style id='15D9882719'></style>
    • <acronym id='15D9882719'></acronym>
      <center id='15D9882719'><center id='15D9882719'><tfoot id='15D9882719'></tfoot></center><abbr id='15D9882719'><dir id='15D9882719'><tfoot id='15D9882719'></tfoot><noframes id='15D9882719'>

    • <optgroup id='15D9882719'><strike id='15D9882719'><sup id='15D9882719'></sup></strike><code id='15D9882719'></code></optgroup>
        1. <b id='15D9882719'><label id='15D9882719'><select id='15D9882719'><dt id='15D9882719'><span id='15D9882719'></span></dt></select></label></b><u id='15D9882719'></u>
          <i id='15D9882719'><strike id='15D9882719'><tt id='15D9882719'><pre id='15D9882719'></pre></tt></strike></i>

          fashion

          fashion

          author:Wikipedia    Page View:462
          David L. Ryan/Boston Globe

          A team of high-powered scientists and billionaire investors said Friday that they’re launching a biomedical institute in Cambridge’s Kendall Square with $500 million in private funding with the aim of shortening the path from research breakthroughs to life-saving medicines.

          The institute, called Arena BioWorks, will put drug discovery and company creation under one roof, upending the traditional model where academic research and venture-backed drug development are separate.

          advertisement

          Backed by deep-pocketed investors including Steve Pagliuca, the former co-chair of Bain Capital and Celtics co-owner, and high-tech mogul Michael Dell, Arena has already lured top scientists from academic labs with lucrative compensation packages, but so far has publicly named only a few.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          How one medical school became remarkably diverse
          How one medical school became remarkably diverse

          ThefirstclassattheUniversityofCalifornia,Davismedicalschool,in1972,waspredominantlywhiteandmale.Chri

          read more
          Biden's order seeks to regulate AI risk without stifling innovation
          Biden's order seeks to regulate AI risk without stifling innovation

          AdobePresidentBidenorderedthenation’sleadinghealthagenciesonMondaytodevelopaplanforregulatingartific

          read more
          New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
          New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

          CMSAdministratorChiquitaBrooks-LaSureChipSomodevilla/GettyImagesWASHINGTON— EliLilly’slatestanti-amy

          read more

          Readout Newsletter: Biogen, Ionis, Johnson & Johnson news

          AdobeTheneed-to-knowthismorningBiogen and IonisPharmaceuticals are endingtheirdevelopment ofanexperi